

Catalysing Change: A Global Health Approach in the Wake of Pandemics

Virtual Panel Discussion · 14 May 2024

10:00 – 11:00 Dakar · 12:00 – 13:00 Berlin, Pretoria · 13:00 – 14:00 Addis Ababa

Biographies (in order of appearance)




Image: © MPI-IB

PROFESSOR DR DR h.c. STEFAN H.E. KAUFMANN • Facilitator (Leopoldina)

Director Emeritus, Max Planck Institute for Infection Biology, Berlin, Germany; Emeritus Group Leader on Systems Immunology, Max Planck Institute for Multidisciplinary Sciences, Göttingen, Germany; Senior Professor, Charité – Universitätsmedizin Berlin, Germany; Faculty Fellow, Hagler Institute for Advanced Study, Texas A&M University, College Station, TX, USA

Stefan H.E. Kaufmann is Founding Director of the Max Planck Institute for Infection Biology in Berlin, Germany, where he now is Director Emeritus. He leads the Emeritus group on systems immunology at the Max Planck Institute for Biophysical Chemistry in Göttingen. He is also Professor of Microbiology and Immunology at Charité University Clinics Berlin, Germany, and a Faculty Fellow of the Hagler Institute for Advanced Study at Texas A&M University, College Station, Texas, USA. His scientific interests include immunity to bacterial pathogens with emphasis on tuberculosis and rational design of vaccines and biosignatures. He is the developer of a tuberculosis vaccine that has reached phase III clinical trial. Kaufmann is former president and honorary member of the German Society for Immunology, former president of the European Federation of Immunological Societies and of the International Union of Immunological Societies. He received numerous prestigious scientific awards, most recently the Gagna A. & Ch. Van Heck Prize. He has more than 900 publications mostly in highranking journals with more than 70,000 citations and an h-index of 141 according to Google Scholar; Thomson/ISI: 111. He is member of numerous professional societies and academies including the German National Academy of Sciences Leopoldina, the American Academy of Microbiology, Berlin-Brandenburg Academy of Sciences and Humanities, World Innovation Foundation, and European Molecular Biology Organization (EMBO).



Image: © CAPRISA

PROFESSOR DR QUARRAISHA ABDOOL KARIM • Facilitator (ASSAf)

Associate Scientific Director of the Centre for the AIDS Programme of Research in South Africa (CAPRISA), Durban, South Africa; Professor in Clinical Epidemiology, Columbia University, New York, USA; Pro-Vice Chancellor for African Health, University of KwaZulu-Natal, South Africa; President, The World Academy of Sciences (TWAS)

Quarraisha Abdool Karim is an infectious diseases epidemiologist whose seminal contributions spanning over three decades have shaped the global HIV prevention landscape, notably in prevention technologies for women. She demonstrated that ARVs prevent sexually transmitted HIV that laid the foundation for HIV pre-exposure prophylaxis (PrEP); and has provided insights in Africa and globally on the impact of Covid-19 on HIV and in the evaluation of Covid-19 vaccines and therapeutics. Abdool Karim is the President of The World Academy of Sciences (TWAS). She is an elected

member of the National Academy of Medicine (USA); and Fellow of The World Academy of Science, Royal Society of South Africa, Academy of Science of South Africa and the African Academy of Science. Her research contributions have been recognized nationally and internationally with over 30 honours including South Africa's Order of Mapungubwe, 2014 TWAS-Lenovo Prize; the John Dirks Canada Gairdner Global Health Award; the 2020 Christophe Mérieux Prize; and the 4th Hideyo Noguchi Africa Prize for Medical Research. She is the Associate Scientific Director of CAPRISA; Professor in Clinical Epidemiology, Columbia University; and Pro-Vice Chancellor for African Health, University of KwaZulu-Natal, South Africa.



Image: © Robert Koch Institute

PROFESSOR DR JOHANNA HANEFELD

Acting Vice President, Robert Koch Institute; Director and Professor, Head of Department, Centre for International Health Protection, Robert Koch-Institute, Germany; Professor of Global Health Policy at the London School of Hygiene and Tropical Medicine, London, UK

Johanna Hanefeld is Vice President (acting) & head of the centre for health protection (ZIG) at the Robert Koch Institute in Berlin. ZIG is the international department of the RKI and hosts the first GOARN WHO Collaborating Centre. She is also Associate Professor in Health Policy and Systems at the London School of Hygiene and Tropical Medicine and Lead of its Berlin office.



Image source:
<https://www.nicd.ac.za/about-us/executives/>

PROFESSOR DR ADRIAN PUREN

Executive Director, National Institute for Communicable Diseases (NICD), Johannesburg, South Africa

Adrian Puren is Executive Director of the NICD since January 2022. Prof Adrian Puren was trained and held a lectureship at the University of the Witwatersrand, before taking on various positions at the NICD. Adrian was appointed as Deputy Director and Head of Virology in 1999 and Head of the Centre for HIV and STIs in 2017. As head of virology, he focused on developing and implementing a range of viral diagnostic platforms in support of the NICD's EPI surveillance programmes and diagnostic support.

Adrian's main interest is in the development of HIV surveillance programmes with a particular focus on HIV incidence and the use of "big data" to inform surveillance, monitoring and evaluation. Prof Puren heads the regional and national endpoint diagnostics laboratory for HVTN-supported vaccine and antibody-mediated preventions trials. He serves as the quality assurance technical manager for the NICD and in this capacity, he has provided support to the National Department of Health's implementation and quality assurance of HIV rapid testing. Prof Puren serves on various expert bodies and the most recent is the South African Lancet Commission on High Quality Health in the era of Sustainable Development Goals.

Source: <https://www.nicd.ac.za/about-us/executives/> (last accessed: 18/04/2024).



Image: © World Health Organization

DR OLIVER MORGAN

Director Pandemic and Epidemic Intelligence Systems, World Health Organization (WHO) Hub for Pandemic and Epidemic Intelligence, Berlin, Germany

Dr. Morgan is a public health leader and epidemiologist with extensive international experience in public health surveillance and emergency response. Dr. Morgan is currently the Director of Pandemic and Epidemic Intelligence Systems for the World Health Organization, based in Berlin. Dr. Morgan has conducted epidemiologic investigations of infectious disease outbreaks, chemical and radiation exposure incidents, natural disasters, and humanitarian civil conflicts. Dr. Morgan has worked for the World Health Organization since 2016, the US Centers for Disease Control and Prevention (2007-2016), and the UK National Health Service/ Health Protection Agency (2002-2007).




Image source: BioNTech

PROFESSOR DR DR PEDRO L. ALONSO

Senior Vice President Science & Medicine, Head of the Global Health Office (GHO), BioNTech, Germany

Prof. Pedro L. Alonso, M.D., Ph.D., joined BioNTech in 2023 as Senior Vice President Science and Medicine and head of the Global Health Office (GHO). Together with his team, he catalyzes and supports BioNTech's efforts to apply innovative science in vaccinology to address some of the largest unmet global public health needs, particularly in Low- and Middle-Income Countries. The vision of the GHO is to achieve impact and promote health equity.

Pedro L. Alonso is a Professor of Global Health at the Faculty of Medicine and Hospital Clinic at the University of Barcelona. Prior to joining BioNTech, he was Director of the Global Malaria Programme at the World Health Organization's headquarters in Geneva, Switzerland. He was the founding director of the Barcelona Institute for Global Health (ISGLOBAL) in 2010 and of the Manhica Health Research Centre (CISM) in Mozambique in 1996.

Pedro L. Alonso is a physician and infectious disease epidemiologist with over 30 years experience in global health and has lived and worked in West-, East-, and Southern Africa, aiming to strengthen research capacities and conducting research into the continent's leading causes of disease and death. He has helped develop improved diagnostic, treatment, and prevention strategies, including vaccines. Additionally, he has overseen more than 20 Ph.D. theses and published over 500 papers in international journals.

He has received several awards including the Ross Medal (University of London) and the Carlos IV award (Spanish Royal Academy of Medicine). Pedro L. Alonso is an international Honorary Fellow of the ASTMH (The American Society of Tropical Medicine and Hygiene) and of the U.S. National Academy of Medicine.

Last updated: 10 May 2024